HS
ADVM

HighVista Strategies’s Adverum Biotechnologies ADVM Stock Holding History

HighVista Strategies’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,491
Closed -$640K – 119
2021
Q1 		$640K Buy
6,491
+1,038
+19% +$125K 0.48% 53
2020
Q4 		$591K Buy
5,453
+1,873
+52% +$232K 0.38% 65
2020
Q3 		$369K Buy
3,580
+960
+37% +$144K 0.27% 67
2020
Q2 		$547K Buy
+2,620
New +$464K 0.45% 18

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HighVista Strategies's ADVM Position: Q2 2021 in Review

HighVista Strategies sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 6,491 shares — an estimated $640K sold.

HighVista Strategies first reported a position in ADVM in Q2 2020 and held it in 4 quarters. The position peaked at $640K in Q1 2021. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • HighVista Strategies reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 6,491 Adverum Biotechnologies shares in Q2 2021, an estimated $640K.
  • HighVista Strategies first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 4 quarters.
  • HighVista Strategies's Adverum Biotechnologies position peaked at $640K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.